聚乙二醇4000治疗老年人慢性功能性便秘

目的 :评价聚乙二醇 40 0 0对老年人慢性功能性便秘的疗效和安全性。方法 :60例年龄在(81±s 5)a的老年功能性便秘病人 ,分为 2组 ,共有 59例病人完成治疗 ,聚乙二醇组 2 9例给予聚乙二醇 40 0 0 ,1 0g,po,bid ;乳果糖组 30例 ,给以乳果糖 ,1 5mL ,po,bid ,疗程均为 2 1d。治疗后观察病人大便次数和大便形状 ,并观察腹胀、食欲不振、大便困难等症状缓解率。结果 :聚乙二醇组经治疗后排便困难发生率由 86 %下降至 34 % ,较治疗前有显著性下降 (P <0 .0 1 ) ,与乳果糖组比较 ,无统计学差异 (P >0 .0 5) ;且在有效病人中服药量小于乳果糖组 ,但 2组相比无统计学差异 ;聚乙二醇组治疗便秘的显效率和有效率分别为 52 %和 1 7% ,与乳果糖组相似 (P >0 .0 5) ;而不良反应发生率为 6 .9% ,与乳果糖组相近 (P >0 .0 5)。结论 :聚乙二醇 40 0 0能安全有效地治疗老年人慢性功能性便秘

Macrogol 4000 in treatment of chronic functional constipation of aged patients

AIM: To evaluate the effect and safety of macrogol 4000 for the chronic functional co nstipation of aged patients. METHODS: Sixty aged patients with chronic functional constipation were divided into two groups. Fivty-nine patients had completed the treatment. Thirty aged patients in macrogol group received macrogol 4000 10 g, po, bid, while 30 ag ed patients in lactulose group received lactulose 15 mL, po, bid. The time s and shape of defecate, and the symptom improvable rate of bloating, anorexia and def ecate-difficulty were observed. RESULTS: After treatment with macrogol 4000, the rate of defecat e-difficulty reduced from 86 % to 34 % with significant statistic difference (P< 0.01 ). The result of the macrogol group was similar to that of the la ctul ose group(P>0.05). The dose of the medicine used in macrogol group was lower than that of the lactulose group, but with no significant differences. The rema rkable effective rate and effective rate of macrogol group was 52 % and 17 %, t hat was similiar to that of lactulose group. And the adverse reaction of macrogo l group was 6.9 %, closed to that of lactulose group. CONCLUSION: Macrogol 4000 is effective and safe in the treatment of chronic fu nctional constipation of aged patients.